Adhezion Biomedical, LLC announced that the just-published 2021 Infusion Therapy Standards of Practice (INS Standards) recognizes tissue adhesive as a standard of care for all vascular access device (VAD) care and management. Adhezion Biomedical’s SecurePortIV is currently the only tissue adhesive cleared for this indication by the U.S. FDA.
SecurePortIV adhesive is a highly versatile cyanoacrylate formulation that can be used with short or long-term vascular access devices to enhance device securement, seal the catheter insertion site, protect a patient from catheter related blood stream infection, and provide a water-resistant barrier — all in a single product.
“It is so exciting to see how this technology, which has been used for years to close wounds, is now being used to secure, seal, and protect our vascular access insertion sites,” shared Marcia Wise, Adhezion’s medical director for Vascular Access. “Rarely in my 30-plus-year career in vascular access have I observed a product move from initial trials to being accepted as a standard of care so quickly. This is a direct result of strong data published and presented by the clinicians listed above.”
The INS Standards are a set of evidence-based practice recommendations that are published every five years, where adherence to the standards promotes consistency in patient care guides clinical decision-making and enhances competency.Each standard is evaluated for the level of evidence supporting that recommendation.
Standards with a large body of evidence are identified as Level I or Level II and carry strong practice recommendations. The evidence levels for the use of tissue adhesive are predominantly Level I or Level II.
“It is gratifying for us to see SecurePortIV recognized for its valuable clinical benefits in such a short time since its launch and to watch it become a disruptive and essential technology in the field of vascular access,” said Pete Molinaro, Adhezion’s CEO and chairman.